ARVN - アルビナス (Arvinas Inc.) アルビナス

 ARVNのチャート


 ARVNの企業情報

symbol ARVN
会社名 Arvinas Inc (アルビナス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 アルヴィーナス(Arvinas Inc.)(旧名: Arvinas Holding Co LLC)は開発段階のバイオ医薬品会社である。同社は、疾患を引き起こすタンパク質を分解する治療法の開発と商品化に従事する。同社は病気を引き起こすタンパク質を選択的かつ効率的に分解・除去するために、身体の天然タンパク質処理システムを利用するように設計されたタンパク質分解誘導キメラ分子(PROTACs)を処理する技術プラットフォームを使用する。同社はPROTACプラットフォームを使用して、臓器系および組織における疾患を標的とするタンパク質分解産物候補パイプラインを構築する。同社はまたARV-110とARV-471のリード製品候補を第1相臨床試験に進めることにも注力する。同社は転移性去勢抵抗性前立腺癌(mCRPC)を有する男性にあるARV-110の第 I 相臨床試験、転移性エストロゲン受容体陽性(ER)とHER2陰性乳癌、またはER +陽性乳癌の女性におけるARV-471の第1相臨床試験を開始する予定である。   アルビナスは米国のバイオ薬品会社。がんをはじめとする治療困難な疾患を引き起こすタンパク質を分解し、除去するタンパク質分解剤の開発・研究を行う。特にアンドロゲン受容体およびエストロゲン受容体を含む前立腺がんや乳がんなどのがんに対して有効性のある分解薬の開発に焦点を当てる。本社所在地はコネチカット州ニュ―ヘブン。   Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC® protein degraders against validated and "undruggable" targets, the company has two clinical-stage programs: ARV-110 for the treatment of men with metastatic castrate-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer.
本社所在地 5 Science Park 395 Winchester Avenue New Haven CT 06511 USA
代表者氏名
代表者役職名
電話番号 +1 203-535-1456
設立年月日 41306
市場名 NASDAQ National Market System
ipoyear 2018年
従業員数 72人
url www.arvinas.com
nasdaq_url https://www.nasdaq.com/symbol/arvn
adr_tso
EBITDA EBITDA(百万ドル) -24.04163
終値(lastsale) 14.99
時価総額(marketcap) 0
時価総額 時価総額(百万ドル) 951.25580
売上高 売上高(百万ドル) 11.74966
企業価値(EV) 企業価値(EV)(百万ドル) 154.54711
当期純利益 当期純利益(百万ドル) -114.01680
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Arvinas Inc revenues increased from $3.3M to $7.5M. Net loss applicable to common stockholders increased from $12.9M to $98.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase of 17% to $17.5M (expense) General and administrative increase of 88% to $2.8M (expense).

 ARVNのテクニカル分析


 ARVNのニュース

   Arvinas Inc (ARVN) President and CEO John G Houston Sold $3.6 million of Shares  2021/06/12 19:15:11 GuruFocus
Related Stocks: ARVN ,
   Arvinas Participates in Groundbreaking Ceremony for New Space Within Downtown Crossing Development in New Haven  2021/06/07 21:19:00 GlobeNewswire
NEW HAVEN, Conn., June 07, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today joined state and local officials, fellow tenants, and community partners, in a groundbreaking ceremony for 101 College Street, a new 525,000-square-foot-building to be constructed as part of New Havens Downtown Crossing revitalization project. Arvinas will lease three of the 10 floors at 101 College and this space will serve as the Companys headquarters beginning in 2024.
   Progressive Supranuclear Palsy Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | DTx Pharma, APRINOIA Therapeutics, Arvinas, Tau-Biologics, AlzProtect and Others  2021/06/04 03:04:02 AB Newswire
   Arvinas to Present at the 42nd Annual Goldman Sachs Global Healthcare Conference  2021/06/03 00:00:00 BioSpace
Arvinas, Inc., a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, announced that Ron Peck, M.D., Chief Medical Officer, and Sean Cassidy, Chief Financial Officer, will participate in a fireside chat at the 42nd Annual Goldman Sachs Global Healthcare Conference on Thursday, June 10 at 10:30 a.m. ET.
   Arvinas Stock Pops On Buy Rating As Biotech Takes On ''Undruggable Targets''  2021/05/21 16:10:02 Investor''s Business Daily
Arvinas'' bid to wrangle "undruggable targets" could reap $4 billion in sales, an analyst said. ARVN stock popped on her rating.
   The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica  2020/12/29 13:09:37 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 28) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Allakos Inc (NASDAQ: ALLK ) Apellis Pharmaceuticals Inc (NASDAQ: APLS ) Arvinas Inc (NASDAQ: ARVN ) Atea Pharmaceuticals, Inc. (NASDAQ: AVIR ) AtriCure Inc. (NASDAQ: ATRC ) BIO-TECHNE Corp (NASDAQ: TECH ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Cellectis SA (NASDAQ: CLLS ) Crispr Therapeutics AG (NASDAQ: CRSP ) Curis, Inc. (NASDAQ: CRIS ) Edwards Lifesciences Corp (NYSE: EW ) ESSA Pharma Inc (NASDAQ: EPIX ) Eton Pharmaceuticals Inc (NASDAQ: ETON ) Evelo Biosciences Inc (NASDAQ: EVLO ) Evogene Ltd (NASDAQ: EVGN ) Inari Medical Inc (NASDAQ: NARI ) Integra Lifesciences Holdings Corp (NASDAQ: IART ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ) Kodiak Sciences Inc (NASDAQ: KOD ) Kymera Therapeutics Inc (NASDAQ: KYMR ) Lumos Pharma Inc (NASDAQ: LUMO ) Medicenna Therapeutics Corp (NASDAQ: MDNA ) Myovant Sciences Ltd (NYSE: MYOV ) - announced a licensing deal with Pfizer Inc.
   ARVN Climbs on Stock Offering  2020/12/15 14:58:42 Baystreet Canada
Arvinas Inc (NASDAQ:ARVN) reported a proposed offering of $250 million of common stock. The New Haven, Conn.-based company, a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation using its PROTAC …
   ROCE Insights For Arvinas  2020/12/15 09:48:00 Benzinga
In Q3, Arvinas (NASDAQ: ARVN) posted sales of $7.60 million. Earnings were up 19.88%, but Arvinas still reported an overall loss of $31.75 million. In Q2, …
   Alexion, Calyxt, Arvinas: 5 Top Stock Gainers for Monday  2020/12/14 18:36:49 The Street
Alexion Pharmaceuticals, Calyxt, Homology Medicines, Arvinas and SandRidge Energy are five top stock gainers for Monday.
   Stocks making the biggest moves midday: DoorDash, Airbnb, Denny's, Virgin Galactic, Arvinas & more  2020/12/14 17:18:47 CNBC
DoorDash and Airbnb get downgraded. Elliott Management takes a stake in Public Storage.
   The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica  2020/12/29 13:09:37 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 28) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Allakos Inc (NASDAQ: ALLK ) Apellis Pharmaceuticals Inc (NASDAQ: APLS ) Arvinas Inc (NASDAQ: ARVN ) Atea Pharmaceuticals, Inc. (NASDAQ: AVIR ) AtriCure Inc. (NASDAQ: ATRC ) BIO-TECHNE Corp (NASDAQ: TECH ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Cellectis SA (NASDAQ: CLLS ) Crispr Therapeutics AG (NASDAQ: CRSP ) Curis, Inc. (NASDAQ: CRIS ) Edwards Lifesciences Corp (NYSE: EW ) ESSA Pharma Inc (NASDAQ: EPIX ) Eton Pharmaceuticals Inc (NASDAQ: ETON ) Evelo Biosciences Inc (NASDAQ: EVLO ) Evogene Ltd (NASDAQ: EVGN ) Inari Medical Inc (NASDAQ: NARI ) Integra Lifesciences Holdings Corp (NASDAQ: IART ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ) Kodiak Sciences Inc (NASDAQ: KOD ) Kymera Therapeutics Inc (NASDAQ: KYMR ) Lumos Pharma Inc (NASDAQ: LUMO ) Medicenna Therapeutics Corp (NASDAQ: MDNA ) Myovant Sciences Ltd (NYSE: MYOV ) - announced a licensing deal with Pfizer Inc.
   ARVN Climbs on Stock Offering  2020/12/15 14:58:42 Baystreet Canada
Arvinas Inc (NASDAQ:ARVN) reported a proposed offering of $250 million of common stock. The New Haven, Conn.-based company, a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation using its PROTAC …
   ROCE Insights For Arvinas  2020/12/15 09:48:00 Benzinga
In Q3, Arvinas (NASDAQ: ARVN) posted sales of $7.60 million. Earnings were up 19.88%, but Arvinas still reported an overall loss of $31.75 million. In Q2, …
   Alexion, Calyxt, Arvinas: 5 Top Stock Gainers for Monday  2020/12/14 18:36:49 The Street
Alexion Pharmaceuticals, Calyxt, Homology Medicines, Arvinas and SandRidge Energy are five top stock gainers for Monday.
   Stocks making the biggest moves midday: DoorDash, Airbnb, Denny's, Virgin Galactic, Arvinas & more  2020/12/14 17:18:47 CNBC
DoorDash and Airbnb get downgraded. Elliott Management takes a stake in Public Storage.

 関連キーワード  (医薬品 米国株 アルビナス ARVN Arvinas Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)